Comment & Analysis

Today's deal between AstraZeneca and Celgene shows that when companies are willing to yield full ...

Ordinarily a $250m up-front payment for a phase I/II asset would seem generous, but when it comes ...

The brace of licensing deals unveiled by AstraZeneca today are remarkable for their generous ...

MedTech

EventAnalyzer

Latest
 

Therapeutic Focus

Market Moving Events

EP Vantage Interviews